Fabián Tibaldi

Follow

Generating author description...

All published works
Action Title Year Authors
+ Tree‐temporal scan statistics for safety signal detection in vaccine clinical trials 2024 François Haguinet
Fabián Tibaldi
Christophe Dessart
Andrew Bate
+ PDF Chat Assurance in vaccine efficacy clinical trial design based on immunological responses 2021 Andrea Callegaro
Toufik Zahaf
Fabián Tibaldi
+ PDF Chat Principal surrogates in context of high vaccine efficacy 2021 Andrea Callegaro
Fabián Tibaldi
Dean Follmann
+ PDF Chat Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy 2019 Andrea Callegaro
Fabián Tibaldi
+ Statistical methods for the analysis of clinical trials data containing many zeros: An application in vaccine development 2014 Andrea Callegaro
Marie Kassapian
Toufik Zahaf
Fabián Tibaldi
+ PDF Chat Nonlinear Fractional Polynomials for Estimating Long-Term Persistence of Induced Anti-HPV Antibodies: A Hierarchical Bayesian Approach 2014 Mehreteab Aregay
Ziv Shkedy
Geert Molenberghs
Marie‐Pierre David
Fabián Tibaldi
+ Nonlinear Fractional Polynomials for Estimating Long-Term Persistence of Induced Anti-HPV Antibodies: A Hierarchical Bayesian Approach 2014 Mehreteab Aregay
Ziv Shkedy
Geert Molenberghs
Marie‐Pierre David
Fabián Tibaldi
+ Linear Categorical Marginal Modeling of solicited symptoms in vaccine clinical trials 2013 Wicher Bergsma
Emmanuel Aris
Fabián Tibaldi
+ Linear Categorical Marginal Modeling of solicited symptoms in vaccine clinical trials 2013 Wicher Bergsma
Emmanuel Aris
Fabián Tibaldi
+ PDF Chat Linear Categorical Marginal Modeling of Solicited Symptoms in Vaccine Clinical Trials 2012 Wicher Bergsma
Emmanuel Aris
Fabián Tibaldi
+ Implementation of a Phase 1 Adaptive Clinical Trial in a Treatment of Type 2 Diabetes 2008 Fabián Tibaldi
Benoît Beck
Alun Bedding
+ PDF Chat Accounting for variability in individual hierarchical clinical trial data 2007 Fabián Tibaldi
Didier Renard
Geert Molenberghs
+ <i>The authors replied as follows:</i> 2007 Ariel Alonso
Geert Molenberghs
Tomasz Burzykowski
Didier Renard
Helena Geys
Ziv Shkedy
Fabián Tibaldi
José Cortiñas Abrahantes
Marc Buyse
+ Joint detection of important biomarkers and optimal dose–response model using penalties 2007 F. Vandenhende
Paul H.C. Eilers
Edouard Ledent
Didier Renard
Fabián Tibaldi
+ Conditional mixed models with crossed random effects 2006 Fabián Tibaldi
Geert Verbeke
Geert Molenberghs
Didier Renard
Wim Van Den Noortgate
Paul De Boeck
+ PDF Chat Prentice's Approach and the Meta‐Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints 2004 Ariel Alonso
Geert Molenberghs
Tomasz Burzykowski
Didier Renard
Helena Geys
Ziv Shkedy
Fabián Tibaldi
José Cortiñas Abrahantes
Marc Buyse
+ Modelling associations between time‐to‐event responses in pilot cancer clinical trials using a Plackett–Dale model 2004 Fabián Tibaldi
Franz Torres Barbosa
Geert Molenberghs
+ PDF Chat Pseudo‐likelihood estimation for a marginal multivariate survival model 2004 Fabián Tibaldi
Geert Molenberghs
Tomasz Burzykowski
Helena Geys
+ PDF Chat Simplified hierarchical linear models for the evaluation of surrogate endpoints 2003 Fabián Tibaldi
José Cortiñas Abrahantes
Geert Molenberghs
Didier Renard
Tomasz Burzykowski
Marc Buyse
Max Parmar
Theo Stijnen
Russ Wolfinger
+ Statistical software for calculating properly weighted estimates form Health Interview Survey Data 2003 Fabián Tibaldi
Herman Van Oyen
Johan Van der Heyden
Liesbeth Bruckers
Geert Molenberghs
+ Multivariate Plackett-Dale inference to study the inheritance of longevity in a Belgian village 2003 Fabián Tibaldi
Bart Van de Putte
Helena Geys
Geert Molenberghs
Koenraad Matthijs
Robert Vlietinck
+ Methodology of the validation of surrogate endpoints in multiple randomized experiments 2001 Geert Molenberghs
Ariel Alonso
Tomasz Burzykowski
Jose Cortinas Abrahantas
Helena Geys
Didier Renard
Ziv Shkedy
Fabián Tibaldi
Marc Buyse
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ PDF Chat The validation of surrogate endpoints in meta-analyses of randomized experiments 2000 Marc Buyse
Geert Molenberghs
Tomasz Burzykowski
Didier Renard
Helena Geys
7
+ Surrogate endpoints in clinical trials: Definition and operational criteria 1989 Ross L. Prentice
7
+ Statistical validation of intermediate endpoints for chronic diseases 1992 Laurence S. Freedman
Barry I. Graubard
Arthur Schatzkin
6
+ PDF Chat Principal Stratification in Causal Inference 2002 Constantine Frangakis
Donald B. Rubin
4
+ Criteria for the Validation of Surrogate Endpoints in Randomized Experiments 1998 Marc Buyse
Geert Molenberghs
4
+ PDF Chat On meta-analytic assessment of surrogate outcomes 2000 Mitchell H. Gail
Ruth M. Pfeiffer
Hans C. van Houwelingen
Raymond J. Carroll
4
+ Meta-analysis for the evaluation of potential surrogate markers 1997 Michael J. Daniels
Michael D. Hughes
4
+ PDF Chat Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points 2001 Tomasz Burzykowski
Geert Molenberghs
Marc Buyse
Helena Geys
Didier Renard
3
+ Advanced methods in meta‐analysis: multivariate approach and meta‐regression 2002 Hans C. van Houwelingen
Lidia R. Arends
Theo Stijnen
3
+ PDF Chat Simplified hierarchical linear models for the evaluation of surrogate endpoints 2003 Fabián Tibaldi
José Cortiñas Abrahantes
Geert Molenberghs
Didier Renard
Tomasz Burzykowski
Marc Buyse
Max Parmar
Theo Stijnen
Russ Wolfinger
3
+ Longitudinal data analysis using generalized linear models 1986 Kung‐Yee Liang
Scott L. Zeger
3
+ Logistic Regression for Correlated Binary Data 1994 Saskia le Cessie
Hans C. van Houwelingen
3
+ A Class of Bivariate Distributions 1965 R. L. Plackett
3
+ Families of Bivariate Distributions 1973 V. S. Huzurbazar
Kanti V. Mardia
3
+ PDF Chat Augmented Designs to Assess Immune Response in Vaccine Trials 2006 Dean Follmann
3
+ Global Cross-Ratio Models for Bivariate, Discrete, Ordered Responses 1986 Jocelyn R. Dale
3
+ Pseudolikelihood Modeling of Multivariate Outcomes in Developmental Toxicology 1999 Helena Geys
Geert Molenberghs
Louise Ryan
3
+ Surrogate End Points in Clinical Trials: Are We Being Misled? 1996 Thomas R. Fleming
2
+ PDF Chat On the Relationship between the Causal-Inference and Meta-Analytic Paradigms for the Validation of Surrogate Endpoints 2014 Ariel Alonso
Wim Van der Elst
Geert Molenberghs
Marc Buyse
Tomasz Burzykowski
2
+ PSEUDOLIKELIHOOD ESTIMATION : SOME EXAMPLES 2016 Barry C. Arnold
David Strauss
2
+ PDF Chat Marginal modelling of multivariate categorical data 1999 Geert Molenberghs
Emmanuel Lesaffre
2
+ Multivariate Models and Multivariate Dependence Concepts 1997 Harry Joe
2
+ Families of Bivariate Distributions. 1971 J. K. Ord
Kanti V. Mardia
2
+ PDF Chat Marginal Modeling of Correlated Ordinal Data Using a Multivariate Plackett Distribution 1994 Geert Molenberghs
Emmanuel Lesaffre
2
+ Use of the false discovery rate for evaluating clinical safety data 2004 Devan V. Mehrotra
Joseph F. Heyse
2
+ PDF Chat Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy 2019 Andrea Callegaro
Fabián Tibaldi
2
+ Multilevel covariance component models 1987 Harvey Goldstein
2
+ PDF Chat The Validation of Surrogate End Points by using Data from Randomized Clinical Trials: A Case-Study in Advanced Colorectal Cancer 2003 Tomasz Burzykowski
Geert Molenberghs
Marc Buyse
2
+ Inferences on the Association Parameter in Copula Models for Bivariate Survival Data 1995 Joanna H. Shih
Thomas Louis
2
+ Simultaneously Modeling Joint and Marginal Distributions of Multivariate Categorical Responses 1994 Joseph B. Lang
Alan Agresti
2
+ PDF Chat On Nonparametric Measures of Dependence for Random Variables 1981 B. Schweizer
Edward F. Wolff
2
+ The Joy of Copulas: Bivariate Distributions with Uniform Marginals 1986 Christian Genest
Jock MacKay
2
+ <b>R2WinBUGS</b>: A Package for Running<b>WinBUGS</b>from<i>R</i> 2005 Sibylle Sturtz
Uwe Ligges
Andrew Gelman
2
+ Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling 1994 Patrick Royston
Douglas G. Altman
2
+ ASTIN: a Bayesian adaptive dose–response trial in acute stroke 2005 Andrew P. Grieve
Michael Krams
1
+ Bivariate Survival Models Induced by Frailties 1989 David Oakes
1
+ PDF Chat Validation of a longitudinally measured surrogate marker for a time-to-event endpoint 2003 Didier Renard
Helena Geys
Geert Molenberghs
Tomasz Burzykowski
Marc Buyse
Tony Vangeneugden
Luc Bijnens
1
+ The advantages and disadvantages of adaptive designs for clinical trials 2004 Péter Bauer
Werner Brannath
1
+ Quantifying the Effect of the Surrogate Marker by Information Gain 2007 Yongming Qu
Michael Case
1
+ Data Mining and Statistically Guided Clinical Review of Adverse Event Data in Clinical Trials 2009 Sue Southworth
Mark O’Connell
1
+ Maximum Likelihood Approaches to Variance Component Estimation and to Related Problems 1977 David A. Harville
1
+ PDF Chat Bayesian probability of success for clinical trials using historical data 2014 Joseph G. Ibrahim
Ming‐Hui Chen
Mani Lakshminarayanan
G. Frank Liu
Joseph F. Heyse
1
+ Bayesian inference for variance components using only error contrasts 1974 David A. Harville
1
+ Approximate Inference in Generalized Linear Mixed Models 1993 N. E. Breslow
David Clayton
1
+ PDF Chat Linear Mixed Models for Longitudinal Data 1997 Geert Verbeke
1
+ PDF Chat Ethically optimised designs. 1982 D. G. Clayton
1
+ Discrete Longitudinal Data 2006 Hulin Wu
Jin‐Ting Zhang
1
+ A Composite Likelihood Approach to Multivariate Survival Data 2001 Erik Thorlund Parner
1
+ Conditional Linear Mixed Models 2001 Geert Verbeke
Bart Spiessens
Emmanuel Lesaffre
1
+ PDF Chat A perfect correlate does not a surrogate make 2003 Stuart G. Baker
Barnett S. Kramer
1